Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

MLA

Larkin, James, et al. “Vemurafenib in Patients with BRAF(V600) Mutated Metastatic Melanoma: An Open-Label, Multicentre, Safety Study.” The Lancet. Oncology, vol. 15, no. 4, Apr. 2014, pp. 436–44. EBSCOhost, https://doi.org/10.1016/S1470-2045(14)70051-8.

APA

Larkin, J., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Espinosa, E., Garbe, C., Sileni, V. C., Gogas, H., Miller, W. H., Jr, Mandalà, M., Hospers, G. A. P., Arance, A., Queirolo, P., Hauschild, A., Brown, M. P., Mitchell, L., Veronese, L., & Blank, C. U. (2014). Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet. Oncology, 15(4), 436–444. https://doi.org/10.1016/S1470-2045(14)70051-8

Chicago

Larkin, James, Michele Del Vecchio, Paolo A Ascierto, Ivana Krajsova, Jacob Schachter, Bart Neyns, Enrique Espinosa, et al. 2014. “Vemurafenib in Patients with BRAF(V600) Mutated Metastatic Melanoma: An Open-Label, Multicentre, Safety Study.” The Lancet. Oncology 15 (4): 436–44. doi:10.1016/S1470-2045(14)70051-8.